Oral Hygiene Protocols and Basic Oral Care in Cancer Patients: A Systematic Review
Abstract
1. Introduction
2. Material and Methods
2.1. Eligibility Criteria
2.2. Information Sources and Search Strategy
2.3. Selection Process
2.4. Data Collection Process and Data Items
2.5. Risk of Bias Assessments
2.6. Effect Measures
3. Results
3.1. Study Selection
3.2. Study Characteristics
3.3. Results of Individual Studies
4. Discussion
5. Limitations
6. Conclusions
7. Other Information
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424, Erratum in CA Cancer J. Clin. 2020, 70, 313. [Google Scholar] [CrossRef]
- Caribé-Gomes, F.; Chimenos-Küstner, E.; López-López, J.; Finestres-Zubeldia, F.; Guix-Melcior, B. Dental management of the complications of radio and chemotherapy in oral cancer. Med. Oral. 2003, 8, 178–187. [Google Scholar] [PubMed]
- Mosel, D.D.; Bauer, R.L.; Lynch, D.P.; Hwang, S.T. Oral complications in the treatment of cancer patients. Oral Dis. 2011, 17, 550–559. [Google Scholar] [CrossRef] [PubMed]
- Epstein, J.B.; Hong, C.; Logan, R.M.; Barasch, A.; Gordon, S.M.; Oberlee-Edwards, L. A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer 2012, 18, 1023–1031. [Google Scholar]
- Burlage, F.R.; Coppes, R.P.; Meertens, H.; Stokman, M.A.; Vissink, A. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiat. Oncol. 2001, 61, 271–274. [Google Scholar] [CrossRef]
- Almståhl, A.; Finizia, C.; Carlén, A.; Fagerberg-Mohlin, B.; Alstad, T. Explorative study on mucosal and major salivary secretion rates, caries and plaque microflora in head and neck cancer patients. Int. J. Dent. Hyg. 2018, 16, 450–458. [Google Scholar] [CrossRef]
- Jensen, S.B.; Jarvis, V.; Zadik, Y.; Barasch, A.; Ariyawardana, A.; Hovan, A. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer 2013, 21, 3223–3232. [Google Scholar] [CrossRef]
- Lanzós, I.; Herrera, D.; Lanzós, E.; Sanz, M. A critical assessment of oral care protocols for patients under radiation therapy in the regional University Hospital Network of Madrid. J. Clin. Exp. Dent. Spain 2015, 27, 613–621. [Google Scholar] [CrossRef]
- De Sanctis, V.; Bossi, P.; Sanguineti, G.; Trippa, F.; Ferrari, D.; Bacigalupo, A. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. Crit. Rev. Oncol./Hematol. 2016, 100, 147–166. [Google Scholar] [CrossRef]
- Moon, D.H.; Moon, S.H.; Wang, K.; Weissler, M.C.; Hackman, T.G.; Zanation, A.M. Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncol. 2017, 72, 98–103. [Google Scholar] [CrossRef]
- Pauli, N.; Johnson, J.; Finizia, C.; Andréll, P. The incidence of trismus and long-term impact on health-related quality of life in patients with head and neck cancer. Acta Oncol. 2013, 52, 1137–1145. [Google Scholar] [CrossRef]
- Nuñez-Aguilar, J.; Fernández-Olavarría, A.; Oliveros-López, L.G.; Torres-Lagares, D.; Serrera-Figallo, M.A.; Gutiérrez-Corrales, A.; Gutiérrez-Pérez, J.L. Evolution of oral health in oral cancer patients with and without dental treatment in place: Before, during and after cancer treatment. J. Clin. Exp. Dent. 2018, 10, 158–165. [Google Scholar] [CrossRef]
- Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—A web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. [Google Scholar] [CrossRef]
- Moola, S.; Munn, Z.; Tufanaru, C.; Aromataris, E.; Sears, K.; Sfetcu, R.; Currie, M.; Lisy, K.; Qureshi, R.; Mattis, P.; et al. Chapter 7: Systematic Reviews of Etiology and Risk. In JBI Manual for Evidence Synthesis; Aromataris, E., Munn, Z., Eds.; JBI: Kingston, Jamaica, 2020. [Google Scholar] [CrossRef]
- Niewald, M.; Fleckenstein, J.; Mang, K.; Holtmann, H.; Spitzer, W.J.; Rübe, C. Dental status, dental rehabilitation procedures, demographic and oncological data as potential risk factors for infected osteoradionecrosis of the lower jaw after radiotherapy for oral neoplasms: A retrospective evaluation. Radiat. Oncol. 2013, 8, 227. [Google Scholar] [CrossRef] [PubMed]
- Bueno, A.C.; Ferreira, R.C.; Barbosa, F.I.; Jham, B.C.; Magalhães, C.S.; Moreira, A.N. Periodontal care in patients undergoing radiotherapy for head and neck cancer. Support Care Cancer 2013, 21, 969–975. [Google Scholar] [CrossRef] [PubMed]
- Regezi, J.A.; Courtney, R.M.; Kerr, D.A. Dental management of patients irradiated for oral cancer. Cancer 1976, 38, 994–1000. [Google Scholar] [CrossRef] [PubMed]
- Stokman, M.A.; Burlage, F.R.; Spijkervet, F.K. The effect of a calcium phosphate mouth rinse on (chemo) radiation induced oral mucositis in head and neck cancer patients: A prospective study. Int. J. Dent. Hyg. 2012, 10, 175–180. [Google Scholar] [CrossRef]
- Kazemian, A.; Kamian, S.; Aghili, M.; Hashemi, F.A.; Haddad, P. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: A double-blind placebo-controlled randomized clinical trial. Eur. J. Cancer Care 2009, 18, 174–178. [Google Scholar] [CrossRef]
- Satheeshkumar, P.S.; Chamba, M.S.; Balan, A.; Sreelatha, K.T.; Bhatathiri, V.N.; Bose, T. Effectiveness of triclosan in the management of radiation-induced oral mucositis: A randomized clinical trial. J. Cancer Res. Ther. 2010, 6, 466–472. [Google Scholar] [CrossRef]
- Samaranayake, L.P.; Robertson, A.G.; MacFarlane, T.W.; Hunter, I.P.; MacFarlane, G.; Soutar, D.S.; Ferguson, M.M. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clin. Radiol. 1988, 39, 291–294. [Google Scholar] [CrossRef]
- Epstein, J.B.; Silverman, S., Jr.; Paggiarino, D.A.; Crockett, S.; Schubert, M.M.; Senzer, N.N.; Lockhart, P.B.; Gallagher, M.J.; Peterson, D.E.; Leveque, F.G. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001, 92, 875–885. [Google Scholar] [CrossRef] [PubMed]
- Leenstra, J.L.; Miller, R.C.; Qin, R.; Martenson, J.A.; Dornfeld, K.J.; Bearden, J.D.; Puri, D.R.; Stella, P.J.; Mazurczak, M.A.; Klish, M.D.; et al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: A phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J. Clin. Oncol. 2014, 32, 1571–1577. [Google Scholar] [CrossRef] [PubMed]
- Sio, T.T.; Le-Rademacher, J.G.; Leenstra, J.L.; Loprinzi, C.L.; Rine, G.; Curtis, A.; Singh, A.K.; Martenson, J.A., Jr.; Novotny, P.J.; Tan, A.D.; et al. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs. Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA 2019, 321, 1481–1490. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Epstein, J.B.; Güneri, P.; Barasch, A. Appropriate and necessary oral care for people with cancer: Guidance to obtain the right oral and dental care at the right time. Support Care Cancer 2014, 22, 1981–1988. [Google Scholar] [CrossRef]
- Huang, B.S.; Wu, S.C.; Lin, C.Y.; Fan, K.H.; Chang, J.T.; Chen, S.C. The effectiveness of a saline mouth rinse regimen and education programme on radiation-induced oral mucositis and quality of life in oral cavity cancer patients: A randomised controlled trial. Eur. J. Cancer Care 2018, 27, e12819. [Google Scholar] [CrossRef]
- Bonnaure-Mallet, M.; Bunetel, L.; Tricot-Doleux, S.; Guérin, J.; Bergeron, C.; LeGall, E. Oral complications during treatment of malignant diseases in childhood: Effects of tooth brushing. Eur. J. Cancer 1998, 34, 1588–1591. [Google Scholar] [CrossRef]
- Meurman, J.H.; Grönroos, L. Oral and dental health care of oral cancer patients: Hyposalivation, caries and infections. Oral Oncol. 2010, 46, 464–467. [Google Scholar] [CrossRef]
- Antunes, H.; Ferreira, E.; Faria, L.; Schirmer, M.; Rodrigues, P.C.; Small, I.; Colares, M.; Bouzas, L.-F.-d.S.; Ferreira, C.-G. Streptococcal bacteraemia in patients submitted to hematopoietic stem cell transplantation: The role of tooth brushing and use of chlorhexidine. Med. Oral Patol. Oral Cir. Bucal 2010, 15, 303–309. [Google Scholar] [CrossRef]
- Autio-Gold, J. The role of chlorhexidine in caries prevention. Oper. Dent. 2008, 33, 710–716. [Google Scholar] [CrossRef]
- Hancock, P.J.; Epstein, J.B.; Sadler, G.R. Oral and dental management related to radiation therapy for head and neck cancer. J. Can. Dent. Assoc. 2003, 69, 585–590. [Google Scholar]
- Foote, R.L.; Loprinizi, C.L.; Frank, A.R.; O’Fallon, J.R.; Gulavita, S.; Twefik, H.H.; Novotny, P. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J. Clin. Oncol. 1994, 12, 2630–2633. [Google Scholar] [CrossRef]
- Laine, P.; Meurman, J.H.; Murtomaa, H.; Lindqvist, C.; Torkko, H.; Pyrhönen, S.; Teerenhovi, L. One-year trial of the effect of rinsing with an amine fluoride–stannous– fluoride-containing mouthwash on gingival index scores and salivary microbial counts in lymphoma patients receiving cytostatic drugs. J. Clin. Periodontol. 1993, 20, 628–634. [Google Scholar] [CrossRef] [PubMed]
- Sudoh, Y.; Cahoon, E.E.; Gerner, P.; Wang, G.K. Tricyclic antidepressants as long-acting local anesthetics. Pain 2003, 103, 49–55. [Google Scholar] [CrossRef] [PubMed]
- Epstein, J.B.; Chin, E.A.; Jacobson, J.J.; Rishiraj, B.; Le, N. The relationships among fluoride, cariogenic oral flora, and salivary flow rate during radiation therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1998, 86, 286–292. [Google Scholar] [CrossRef] [PubMed]
- Meyerowitz, C.; Watson, G.E., 2nd. The efficacy of an intraoral fluoride-releasing system in irradiated head and neck cancer patients: A preliminary study. J. Am. Dent. Assoc. 1998, 129, 1252–1259. [Google Scholar] [CrossRef]
- Epstein, J.B.; van der Meij, E.H.; Lunn, R.; Stevenson-Moore, P. Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1996, 82, 268–275. [Google Scholar] [CrossRef]
- National Comprehensive Cancer Network. Head and Neck Cancers (Version3.2021). 2021. Available online: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed on 18 August 2021).
- Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015, 349, g7647. [Google Scholar] [CrossRef]
- Cuzzullin, M.C.; Pérez-de-Oliveira, M.E.; Normando, A.G.C.; Santos-Silva, A.R.; Prado-Ribeiro, A.C. Basic oral care in cancer patients: A systematic review. PROSPERO CRD42022319455. Available online: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022319455 (accessed on 5 March 2022).
- Page, M.J.; Moher, D.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ 2021, 372, n160. [Google Scholar] [CrossRef]
Trial design and identification |
|
Ethics and registration |
|
Population |
|
Oral care intervention |
|
Author, Year | Condition | Moment of the Dental Intervention | Dental Intervention | Main Results | Conclusion |
---|---|---|---|---|---|
Epstein, 2001 [22] | Mucositis | Before, during, and after oncologic treatment | Benzydamine—to rinse 1.5 mg/mL benzydamine [15 mL] for 2 min, 4–8 times daily before and during RT, and for 2 weeks after completion of RT) and a Control group—placebo (excipients included 10% alcohol by volume, menthol, peppermint oil, clove oil, and other flavoring agents). | Benzydamine produced a 26.3% reduction in mean mucositis compared with placebo for the overall 0–5000 cGy interval. Moreover, benzydamine produced statistically significant reductions in mucositis in the highest two RT intervals compared with placebo: 36% in the 2500–3750-cGy interval and 25.3% in the 3750–5000-cGy interval. In addition, in a prophylactic use of benzydamine, mucositis scores in oropharyngeal areas at risk for ulceration in both treatment groups remained with no ulceration at cumulative RT exposures of 3750 and 5000 cGy. | The use of benzydamine 0.15% oral rinse is significant as a routine prophylactic in patients with head and neck carcinoma receiving a variety of RT regimens. |
Kazemian, 2009 [19] | Mucositis | Before and during the oncologic treatment | Benzydamine—to rinse with 15 mL of 0.15% for 2 min, 4 times a day from the first day of RT to the end of the treatment | Benzydamine produced a statistically significant reduction in mucositis during RT. There was a statistically significant difference in the grade 3 mucositis in the two groups, which was 43.6% (n = 17) in the benzydamine group and 78.6% (n = 33) in the placebo group. Grade 3 mucositis was 2.6 times more frequent in the placebo group. | Benzydamine 0.15% oral rinse was safe and well-tolerated. It significantly reduced RT-induced mucositis, which also decreased the interruption of the treatment by the patients. The prophylactic usage may decrease the mucosal complications of RT. |
Control group—Placebo. | |||||
Leenstra, 2014 [23] | Mucositis | During the oncologic treatment | Doxepin to rinse with a solution of doxepin 25 mg, diluted to 5 mL with 2.5 mL of sterile or distilled water. | The mean mouth and throat pain reduction was greater for doxepin (−9.1) compared with placebo. Crossover analysis of the two phases showed intrapatient changes of 4.1 for the doxepin–placebo arm and −2.8 for the placebo–doxepin arm; the treatment difference of doxepin versus placebo was −3.5; there was an average mouth and throat pain score reduction of −2.0 (36.3%) from baseline for doxepin compared with −1.0 (18.9%) for placebo at 30 min after rinse. | Doxepin rinse is statistically significantly superior to a placebo in treating oral mucositis pain from head and neck radiotherapy with or without chemotherapy. |
Control group—placebo rinse prepared in a similar manner. | |||||
Samarannayake, 1988 [21] | Mucositis | During the oncologic treatment | Chlorhexidine [to rinse with 15 mL of 0.2% aqueous chlorhexidine gluconate (Hibitane-ICI Pharmaceuticals) for 30 s twice daily] | The yeast carriage rate was significantly higher than the coliform carriage rate in both groups (p < 0.05). The most common coliform found was Klebsiella pneumoniae. Patients using chlorhexidine presented less discomfort. The loss of weight in the control group was four times higher than the study group. The difference noted was highly significant (t = 3.73; df = 22; p < 0.01). | Patients’ acceptance of chlorhexidine is better than benzydamine, but there is little difference between the two mouthwashes both in controlling pain and mucositis or in the oral carriage of the microorganisms studied. |
Benzydamine [to rinse with 15 mL of 0.15% benzydamine hydrochloride (‘Difflam’, Carnegie Medical)] | |||||
Satheeshkumar, 2010 [20] | Mucositis | During the oncologic treatment | Triclosan mouth rinse [to rinse with M/S Colgate Palmolive India Ltd. (Colgate Plax) containing triclosan 0.03%] | From grade 2–3, there was no statistical difference between the study and control groups. The effect of treatment in control of severity of mucositis found significant statistic difference at a very higher level (p < 0.001). With regard to reversal of mucositis from grade 3 to grade 0, the study group had taken only a mean of 23.6 days in place of 36.5 days in the control group. | The calcium phosphate mouth rinse seems to have no influence on the frequency, duration, and severity of oral mucositis during CRT in patients with head and neck cancer. |
Control group—Sodium bicarbonate (2 g of sodium bicarbonate powder) | |||||
Sio, 2019 [24] | Mucositis | During the oncologic treatment | Doxepin—(92 patients to rinse with doxepin mouthwash [25 mg/5 mL water]; 91 patients to diphenhydramine–lidocaine–antacid; and 92 patients to placebo). | Mucositis pain during the first 4 h decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine–lidocaine–antacid mouthwash group, and by 8.7 points in the placebo group. More drowsiness was reported with doxepin mouthwash vs. placebo (by 1.5 points), unpleasant taste (by 1.5 points), and stinging or burning (by 4.0 points). | The use of doxepin mouthwash or diphenhydramine–lidocaine–antacid mouthwash vs. placebo significantly reduced oral mucositis pain during the first 4 h after administration. |
Calcium phosphate (to rinse twice with 15 mL solution for 1 min, four times a day) | |||||
Stokman, 2012 [18] | Mucositis | During the oncologic treatment | Calcium phosphate (to rinse twice with 15 mL solution for 1 min, four times a day) | The mean weight loss after 6 weeks of radiation was 4.0 kg (SD 3.7) in the CP mouth rinse group and 3.5 kg (SD 3.1) in the control group (p = 0.7). Use of gastric tubes was necessary in 12 of the 25 patients in the CP mouth rinse group (55%) and in 6 of the 11 patients in the control group (48%) (p = 0.8). No significant difference was found for oral pain between both groups. | The CP mouth rinse seems to have no influence on the frequency, duration, and severity of oral mucositis during (chemo) radiation in patients with head and neck cancer. |
Control group—salt/baking soda solution (1 tsp. of salt and 1 tsp. of baking soda in a liter of tap water) at least eight times a day to remove sticky saliva and debris. | |||||
Bueno, 2013 [16] | Biofilm | Prior to the oncologic treatment | 1.Oral hygiene instructions included instruction on brushing and interdental cleaning; 2. Coronal scaling (using an ultrasonic instrument), and polishing; 3. A kit containing a toothbrush and toothpaste; 4. The patients were prescribed 1% neutral fluoride solution to be used once daily, designed to prevent caries and postoperative sensitivity. The use of other mouthwashes was not allowed. | Reduction in PD (probing depth) between the T0/T1 and T0/T2; 2. Reduction in the frequency of PI (plaque index) and BOP (bleeding on probing) observed between the baseline assessment and 180 days after RT | Patients undergoing RT to the head and neck region with or without CT do not show aggravations of their clinical periodontal status for up to 6 months after cancer treatment if they also receive periodontal therapy and maintenance. |
During the oncologic treatment | 1.Coronal polishing; 2. Topical application of 1% neutral fluoride gel; 3. Reinforcement of oral hygiene | ||||
After the oncologic treatment | 1. Coronal polishing; 2. Topical application of 1% neutral fluoride gel; 3. Reinforcement of oral hygiene | ||||
Nunez-Aguilar, 2018 [12] | Biofilm | Prior to, during, and after the oncologic treatment | 1. Teaching of oral hygiene, treatment of fluoride and chlorhexidine, scaling and polishing, scaling and root planning, selective carvings, prevention of bedsores in the oral mucosa teeth with sharp edges billed, prosthetic review, fillings, and dental extractions. 2. Teaching of oral hygiene, and use of chlorhexidine and fluoride. 3. Survey before the oncological treatment, after starting the treatment, and with 60% of the treatment complete. | 47.78% of the patients indicated that they had not had sore gums during CRT in the experimental group against 87.5% in the control group; in the experimental group, 17.07% patients had not had bleeding gums during CRT; in the control group, 35 patients had had bleeding gums; in the experimental group, 9.75% patients had ulcers during CRT; in the control group, it was 87.5% patients. In the experimental group, 17.07% of the patients had bleeding gums after CRT; in the control group, 87.80%. | Implementation of prevention protocols and the improvement in oral health among these patients is necessary. |
Niewald, 2013 [15] | Osteoradionecrosis | Prior to the oncologic treatment | 1. Tooth extraction (followed up by an interval of at least 7–10 days using soft diet, valid antibiosis, and prosthodontic abstention) with primary tissue closure; 2. Endodontic treatment; 3. Removal of root remainders with primary tissue closure; 4. Conserving treatment. | 12% of the patients were found to have developed infected osteoradionecrosis during follow-up. The one-year prevalence was 5%, the two- and three-year prevalence 15%— treated by conventionally fractionated RT applying doses of 50 Gy (1 pat.), 60 Gy (4 pats.), 64 Gy (3 pats.), and 70 Gy (3 pats.), respectively. We found 14% of the patients having been operated on had IORN compared to only 8% in the non-surgical patients. | Meticulous dental care resulted in an incidence of IORN of 12%; all of them had undergone conventionally fractionated radiotherapy; in the hyperfractionated group, no IORN occurred at all. |
During the oncologic treatment | Fluoridation was performed according to dental advice. | ||||
After the oncologic treatment | 1. Patients were advised not to wear their dental prostheses up to 6–12 months after RT; 2. Tooth extraction with primary tissue closure; 3. Tooth extraction with primary tissue closure and conservative treatment; 4. Conservative treatment. | ||||
Regezi, 1976 [17] | Osteonecrosis, mucositis, dysgeusia, and dysphagia | Prior to the oncologic treatment | 1. Extraction of no salvageable teeth (teeth with gross dental caries, periapical pathology, advanced periodontal disease, and teeth supported by neoplasm); 2. Dental prophylaxis; 3. Restorative dental procedures as needed; 4. Initiation of oral hygiene regimen: a. Tooth brush instruction with soft brushes (patients were instructed to brush q.i.d. and to follow each brushing with oral lavage and fluoride rinse); b. Oral lavage instruction (1 L warm water with 1 teaspoon each of NaCI and NaHC03); c. Sodium fluoride rinse instruction (1 teaspoon 3yo NaF held in mouth 1 min, then expectorated). This rinse was discontinued during acute mucositis because of mucosal irritation. | Oral hygiene status went from fair/poor at initial examination to good/fair after radiation therapy; patients had normal healthy periodontium (25%), gingivitis (25%), and mild to moderate periodontitis (50%). Periodontal disease did not progress at a rate greater than we would expect in a non-irradiated population. Teeth decay increased 20% following irradiation. All patients had mucositis, which became evident after 2 to 4 weeks of therapy (dysgeusia, dysphagia, dysorhexia, and pain). Overgrowth of Candida albicans was demonstrated in these patients. These symptoms subsided in 3 to 4 weeks after therapy | It can be concluded from the data presented that the complications of osteoradionecrosis, dental caries, and periodontal disease associated with radiation therapy for oral cancer can be reasonably well-controlled using the regimen employed in this study. |
During the oncologic treatment | 1. Weekly prophylaxis with fluoridated polishing paste; 2. Prescriptions for pain relievers, dietary supplements, and antifungal or antibiotic agents when needed. | ||||
After the oncologic treatment | 1. Oral and neck examination for detection of recurrent or new neoplastic diseases; 2. Dental prophylaxis; 3. Restoration dental procedures as needed; 4. Reinforcement of the previously instituted oral hygiene regimen. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cuzzullin, M.C.; Wanderley, M.I.A.; Pérez-de-Oliveira, M.E.; Normando, A.G.C.; Araújo, A.L.D.; Ramos, J.C.; Brandão, T.B.; Epstein, J.B.; Santos-Silva, A.R.; Prado-Ribeiro, A.C. Oral Hygiene Protocols and Basic Oral Care in Cancer Patients: A Systematic Review. Hygiene 2025, 5, 45. https://doi.org/10.3390/hygiene5040045
Cuzzullin MC, Wanderley MIA, Pérez-de-Oliveira ME, Normando AGC, Araújo ALD, Ramos JC, Brandão TB, Epstein JB, Santos-Silva AR, Prado-Ribeiro AC. Oral Hygiene Protocols and Basic Oral Care in Cancer Patients: A Systematic Review. Hygiene. 2025; 5(4):45. https://doi.org/10.3390/hygiene5040045
Chicago/Turabian StyleCuzzullin, Maria Cláudia, Marcelo Ivander Andrade Wanderley, Maria Eduarda Pérez-de-Oliveira, Ana Gabriela Costa Normando, Anna Luíza Damaceno Araújo, Joab Cabral Ramos, Thaís Bianca Brandão, Joel B. Epstein, Alan Roger Santos-Silva, and Ana Carolina Prado-Ribeiro. 2025. "Oral Hygiene Protocols and Basic Oral Care in Cancer Patients: A Systematic Review" Hygiene 5, no. 4: 45. https://doi.org/10.3390/hygiene5040045
APA StyleCuzzullin, M. C., Wanderley, M. I. A., Pérez-de-Oliveira, M. E., Normando, A. G. C., Araújo, A. L. D., Ramos, J. C., Brandão, T. B., Epstein, J. B., Santos-Silva, A. R., & Prado-Ribeiro, A. C. (2025). Oral Hygiene Protocols and Basic Oral Care in Cancer Patients: A Systematic Review. Hygiene, 5(4), 45. https://doi.org/10.3390/hygiene5040045